Stagno J, Deme J, Dwivedi V, Lee Y, Lee H, Yu P
Nucleic Acids Res. 2025; 53(5).
PMID: 40071935
PMC: 11897892.
DOI: 10.1093/nar/gkaf156.
Shi J, Zhang Z, Chen H, Yao Y, Ke S, Yu K
Mol Ther. 2025; 33(3):1073-1090.
PMID: 39905727
PMC: 11897759.
DOI: 10.1016/j.ymthe.2025.01.047.
Nagaretnam I, Kakimoto Y, Yoneshige A, Takeuchi F, Sakimura T, Sato K
Discov Immunol. 2025; 4(1):kyae018.
PMID: 39839810
PMC: 11744370.
DOI: 10.1093/discim/kyae018.
Schoenherr C, Pietzsch S, Barca C, Muller F, Bahr F, Kasten M
Front Mol Med. 2025; 4():1487526.
PMID: 39834851
PMC: 11743445.
DOI: 10.3389/fmmed.2024.1487526.
Masubuchi T, Chen L, Marcel N, Wen G, Caron C, Zhang J
Sci Immunol. 2025; 10(103):eads6295.
PMID: 39752535
PMC: 11774210.
DOI: 10.1126/sciimmunol.ads6295.
Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer.
Gao H, Chen Z, Yao Y, He Y, Hu X
Front Oncol. 2024; 14:1453090.
PMID: 39634266
PMC: 11614734.
DOI: 10.3389/fonc.2024.1453090.
Extraordinary diversity of the CD28/CTLA4 family across jawed vertebrates.
Quiniou S, Clark T, Bengten E, Rast J, Ohta Y, Flajnik M
Front Immunol. 2024; 15:1501934.
PMID: 39606244
PMC: 11599192.
DOI: 10.3389/fimmu.2024.1501934.
STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition.
Fan A, Sultan H, Kumai T, Fesenkova V, Wu J, Klement J
Mol Cancer Ther. 2024; 24(3):419-430.
PMID: 39582348
PMC: 11879759.
DOI: 10.1158/1535-7163.MCT-24-0505.
4E-BP3 deficiency impairs dendritic cell activation and CD4 T cell differentiation and attenuates α-myosin-specific T cell-mediated myocarditis in mice.
Li S, Tajiri K, Yuan Z, Murakata Y, Song Z, Mizuno S
Basic Res Cardiol. 2024; 120(1):225-240.
PMID: 39516410
DOI: 10.1007/s00395-024-01089-3.
Flotillin-2 dampens T cell antigen sensitivity and functionality.
Moon S, Zhao F, Uddin M, Tucker C, Karmaus P, Fessler M
JCI Insight. 2024; 9(24).
PMID: 39499901
PMC: 11665568.
DOI: 10.1172/jci.insight.182328.
Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).
Abulizi A, Yan G, Xu Q, Muhetaer R, Wu S, Abudukelimu K
Sci Rep. 2024; 14(1):25919.
PMID: 39472591
PMC: 11522629.
DOI: 10.1038/s41598-024-75099-5.
Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.
Milutinovic S, Jancic P, Jokic V, Petrovic M, Dumic I, Rodriguez A
Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39459012
PMC: 11510316.
DOI: 10.3390/ph17101372.
The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors.
Gamero M, Patel A, Storozynsky E
Curr Cardiol Rep. 2024; 26(12):1487-1498.
PMID: 39441327
PMC: 11668830.
DOI: 10.1007/s11886-024-02147-x.
Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).
Mousa A, Enk A, Hassel J, Reschke R
Cells. 2024; 13(19.
PMID: 39404378
PMC: 11475876.
DOI: 10.3390/cells13191615.
Therapeutic implications for the PD-1 axis in cerebrovascular injury.
Feghali J, Jackson C
Neurotherapeutics. 2024; 22(1):e00459.
PMID: 39368872
PMC: 11840351.
DOI: 10.1016/j.neurot.2024.e00459.
Immune checkpoint inhibitors in infectious disease.
King H, Lewin S
Immunol Rev. 2024; 328(1):350-371.
PMID: 39248154
PMC: 11659942.
DOI: 10.1111/imr.13388.
Toxicity in the era of immune checkpoint inhibitor therapy.
Keam S, Turner N, Kugeratski F, Rico R, Colunga-Minutti J, Poojary R
Front Immunol. 2024; 15:1447021.
PMID: 39247203
PMC: 11377343.
DOI: 10.3389/fimmu.2024.1447021.
Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases.
Buch M, Mallat Z, Dweck M, Tarkin J, ORegan D, Ferreira V
Nat Rev Rheumatol. 2024; 20(10):614-634.
PMID: 39232242
DOI: 10.1038/s41584-024-01149-x.
Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma.
Liu Y, Ye S, He S, Chi D, Wang X, Wen Y
Nat Commun. 2024; 15(1):7713.
PMID: 39231979
PMC: 11375053.
DOI: 10.1038/s41467-024-52153-4.
Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?.
Jaing T, Wang Y, Chiu C
Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204096
PMC: 11357301.
DOI: 10.3390/ph17080991.